Snoqualmie, Wash.-based Light Sciences Oncology, a developer of light-activated cancer drugs, raised $30 million in a second funding round, even though it still has an IPO registration on file with the SEC. The latest funding closes out the company’s second round, which includes a $15 million investment by Fidelity Investments I wrote about here.
The company didn’t name its latest investors in its press release, but according to VentureWire they include Lehman Brothers, the hedge fund Deephaven Capital Management, the Malaysian Life Sciences Capital Fund, and Burrill & Co.
Test line: Technorati Profile
Tags: biotechnology, cancer, co:Light-Sciences-Oncology, deal, inv:Burrill-&-Co., inv:Deephaven-Capital-Management, inv:Fidelity-Investments, inv:Lehman-Brothers, inv:Malaysian-Life-Sciences-Capital-Fund
1:34 pm
VentureBeat » Life sciences briefing: Monday, Feb. 11, 2008 said:
[...] statement in April 2006, but hasn’t amended it since September of that year. Light Sciences raised $30 million in a second funding round last July, despite its still-active IPO registration. For more stories [...]